CD1D抗体;CD1D Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD1D mouse mAb (green) and negative control (red).    

  
  

CD1d antibodies are essential tools for studying the function of CD1d, a non-classical major histocompatibility complex (MHC) class I-like molecule. CD1d is primarily expressed on antigen-presenting cells, such as dendritic cells, B cells, and intestinal epithelial cells. Unlike MHC molecules that present peptide antigens, CD1d binds lipid-based antigens and presents them to invariant natural killer T (iNKT) cells, a specialized T cell subset bridging innate and adaptive immunity. This interaction activates iNKT cells, triggering rapid cytokine production and modulating immune responses against infections, tumors, and autoimmune diseases.

CD1d antibodies are used to detect CD1d expression in tissues, block CD1d-antigen presentation, or modulate iNKT cell activity in experimental models. They have been instrumental in elucidating CD1d's role in lipid metabolism, mucosal immunity, and diseases like inflammatory bowel disease, multiple sclerosis, and cancer. Therapeutic applications are also emerging; anti-CD1d antibodies are being explored to suppress harmful immune reactions in autoimmunity or enhance antitumor responses. Additionally, CD1d-targeting antibody-drug conjugates are under investigation for precision cancer therapies. However, CD1d's conservation across species and its complex ligand-binding properties pose challenges in antibody development. Recent advances in structural biology and hybridoma technology have improved antibody specificity, aiding both basic research and clinical translation. Ongoing clinical trials (e.g., NCT04887298) highlight the growing interest in CD1d-based immunotherapies.